TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07409272: A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metas

Sponsor: Astellas Pharma Global Development, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 614 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$10,431,036

Rescue Site Savings

+$6,888,420

Unlock Full NCT07409272 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07409272 Rescue Dossier →